What the study found
The article argues that zuranolone’s approval for postpartum depression was a case study in a rapid regulatory process, while approval for major depressive disorder was denied. The authors also state that the process reflected recent policy shifts that lowered the threshold for evidence of benefit.
Why the authors say this matters
The authors conclude that regulatory bodies may be failing in their role as gatekeepers. They suggest that approval standards that rely on smaller trial sets and surrogate outcomes may skew the balance between potential benefits and potential harms in ways that are not in the public’s best interest.
What the researchers tested
The article examines the clinical trial data submitted by the manufacturer for zuranolone. It also reviews the approval path, including priority review and fast-track designation, and discusses how recent regulatory changes may affect drug evaluation.
What worked and what didn't
Zuranolone received US Food and Drug Administration approval for postpartum depression in August 2023 after a 7-month process. Approval for major depressive disorder was denied, and the authors note that fast-track designation can allow fewer trials and focus evaluation on surrogate rather than clinically relevant outcomes.
What to keep in mind
The abstract does not provide the detailed trial findings, specific outcomes, or numerical results from the submitted studies. It also does not describe limitations beyond the authors’ broader concern about regulatory policy and evidence thresholds.
Key points
- Zuranolone was approved in the US for postpartum depression in August 2023.
- Approval for major depressive disorder was denied.
- The approval process took 7 months because the drug received priority review and fast-track designation.
- The authors say fast-track designation can allow fewer trials and use surrogate outcomes instead of clinically relevant ones.
- The article presents zuranolone as a case study of recent developments in drug regulatory sciences.
Disclosure
- Research title:
- Zuranolone was approved for postpartum depression, not major depressive disorder
- Authors:
- Lisa Cosgrove, Milutin Kostić, Barbara Mintzes, Gianna D'Ambrozio, Allen F. Shaughnessy
- Institutions:
- Cambridge Health Alliance, The University of Sydney, University of Belgrade, University of Massachusetts Boston, University of Massachusetts Boston
- Publication date:
- 2026-02-04
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.